Navigation Links
NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
Date:11/9/2009

;, and the other NAI on the market, Relenza®, is contraindicated for this population." said Dr. Moss.

ABOUT NEXBIO

NexBio, Inc. is a privately held clinical-stage biopharmaceutical company located in San Diego. NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase®), is an investigational drug that consists of an inhaled recombinant fusion protein. It inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under BAA Contract HHSN266200600015C and grant U01-AI070281. Viradin(TM), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP® is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP® is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

'/>"/>
SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Results to Be Held at 9:00 A.M. -, EXTON, ... quarter and year end financial results for 2007 and,guidance for ... before the open of the U.S. financial markets., The ... at 9:00,a.m. Eastern Time on the same day. During the ...
... Ill., Feb. 12 The Board of,Directors of Baxter ... dividend of $0.2175 per share of Baxter common stock., ... rate, which was,increased earlier this year by 30 percent. ... shareholders of record as of March 10, 2008., ...
... Lung and Brain Tumor ... Treatment, ... leader in the field of radiosurgery,today announced key clinical presentation highlights from ... Ariz., At this year,s CyberKnife Users, meeting eight presentations reported,on large ...
Cached Biology Technology:ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008 2CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 2CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 3CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 4
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
... of a study this week that they say will help ... or reversing the devastating tissue inflammation that results after heart ... the Journal of Biological Chemistry , lead author Alejandro ... Cardiovascular Science are reporting that vascular cells, ability to properly ...
... in German . Digger wasps of the genus ... their cocoons that guarantee protection against harmful microorganisms. Scientists ... Jena teamed up with researchers at the University of ... Research Hans-Knoell-Institute - and discovered that bacteria of ...
... BIRMINGHAM, Ala. African-Americans age 65 and younger are more ... Caucasians in any region, and people who have a stroke ... according to researchers at the University of Alabama at Birmingham ... UAB,s Reasons for Geographic and Racial Differences in Stroke (REGARDS) ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: